Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

    Diabetes, Obesity and Metabolism Date published:

  • SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

    Diabetes Date published:

  • Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis

    Diabetes, Obesity and Metabolism Date published:

  • Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes by Baseline Loop Diuretic Use: Data from the CREDENCE Trial

    Journal of the American Society of Nephrology Date published:

  • Renal, Cardiovascular (CV), and Safety Outcomes of Canagliflozin (CANA) According to Baseline Albuminuria: A CREDENCE Secondary Analysis

    Journal of the American Society of Nephrology Date published:

  • Associations Between TNFR-1, TNFR-2, and KIM-1 with Kidney and Cardiovascular Outcomes: Results from the CANVAS Trial

    Journal of the American Society of Nephrology Date published:

  • Acute Declines in eGFR During Treatment with Canagliflozin (CANA) and Its Implications for Clinical Practice: Insights from CREDENCE

    Journal of the American Society of Nephrology Date published:

  • The SGLT2 Inhibitor Canagliflozin Reduces the Plasma Markers TNFR-1, TNFR-2, and KIM-1 in the CANVAS Trial

    Journal of the American Society of Nephrology Date published:

  • Canagliflozin Treatment Reduces Formation and Increases Degradation of Collagen Type III in the Canagliflozin Cardiovascular Assessment Study (CANVAS)

    Journal of the American Society of Nephrology Date published:

  • Canagliflozin and Risk of Genital Infections and Urinary Tract Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

    Journal of the American Society of Nephrology Date published:

  • Canagliflozin and Risk of Skin and Soft Tissue Infections in People with Diabetes Mellitus and Kidney Disease in the CREDENCE Trial

    Journal of the American Society of Nephrology Date published:

  • Effects of Canagliflozin on Major Adverse Cardiovascular Events in Patients with Different Baseline Levels of Type 2 Diabetes Disease Severity: Results from the CANVAS Program

    Journal of the American Society of Nephrology Date published:

  • Canagliflozin Across the Spectrum of Kidney Function and Albuminuria: Integrated Data from CANVAS and CREDENCE

    Journal of the American Society of Nephrology Date published:

  • Risk of Hospitalization for Heart Failure (HHF) by eGFR and Urinary Albumin-to-Creatinine Ratio (UACR): Pooled Analyses from the CANVAS Program and CREDENCE

    Journal of the American Society of Nephrology Date published:

  • Early Change in Albuminuria with Canagliflozin (CANA) Predicts Kidney and Cardiovascular (CV) Outcomes

    Journal of the American Society of Nephrology Date published:

  • Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs

    Journal of the American Society of Nephrology Date published: